Valuation : Aclaris Therapeutics, Inc.

Market Cap 885M 762M 715M 652M 1.23B 84.55B 1.23B 8.48B 3.31B 42.68B 3.32B 3.25B 142B P/E 2026 *
-9.2x
P/E 2027 * -7.43x
Enterprise Value 732M 630M 591M 540M 1.02B 69.92B 1.02B 7.01B 2.74B 35.29B 2.75B 2.69B 117B EV / Sales 2026 *
116x
EV / Sales 2027 * 142x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
1 day-2.44%
1 week-6.24%
Current month+15.58%
1 month+12.76%
3 months+31.51%
6 months+109.41%
Current year+99.67%
1 week 5.95
Extreme 5.95
6.6
1 month 5.01
Extreme 5.01
6.6
Current year 2.49
Extreme 2.49
6.6
1 year 1.74
Extreme 1.74
6.6
3 years 0.59
Extreme 0.5902
8.28
5 years 0.59
Extreme 0.5902
19.97
10 years 0.59
Extreme 0.5902
33.25
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
8/1/26 Fiscal year

Chief Technology Officer

85,135 0.0610%
6/4/26
Aisling Capital Management LP
OtherCompany 0 0%
5/1/26 Fiscal year

Chief Technology Officer

82,080 0.0681%
Change 5-day change 1-year change 3-year change Capi.($)
-2.44%-6.24%+226.63%-8.94% 885M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.06%-2.36%+76.04%+172.27% 28.28B
Weighted average by Cap. -1.93%-1.52%+57.68%+152.32%

Financials

2026 *2027 *
Net sales 6.29M 5.42M 5.08M 4.64M 8.74M 601M 8.76M 60.26M 23.51M 303M 23.6M 23.09M 1.01B 5.18M 4.46M 4.19M 3.82M 7.2M 495M 7.22M 49.67M 19.38M 250M 19.45M 19.03M 829M
Net income -91.02M -78.43M -73.54M -67.13M -126M -8.7B -127M -872M -340M -4.39B -342M -334M -14.56B -114M -98.42M -92.28M -84.24M -159M -10.92B -159M -1.09B -427M -5.51B -429M -420M -18.27B
Net Debt -153M -132M -124M -113M -213M -14.63B -213M -1.47B -573M -7.39B -575M -562M -24.49B -147M -126M -118M -108M -204M -14.01B -204M -1.4B -548M -7.07B -550M -538M -23.44B
Logo Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
71
Date Price Change Volume
26-08-28 US$6.010 -2.44% 1,220,839
26-08-27 US$6.160 -0.48% 1,408,995
26-08-26 US$6.190 -5.28% 1,736,052
26-08-25 US$6.535 +3.57% 3,353,244
26-08-24 US$6.310 -1.56% 1,272,816
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6.010USD
Average target price
10.20USD
Spread / Average Target
+69.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACRS Stock